Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 10:30 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1945–1968 of 2,704 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Autologous hematopoietic stem cell transplantation Clear all

Conditions: Monoclonal Gammopathy, Smoldering Myeloma, Myeloma
Interventions: DKK1; Biological
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 2
States / cities: Cleveland, Ohio

Conditions: Breast Cancer
Interventions: CS-1000 labeled SVF cells; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2022
U.S. locations: 1
States / cities: Lutherville-Timonium, Maryland

Conditions: Renal Cell Carcinoma
Interventions: MB-002; Biological
Lead sponsor: Argos Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 3
States / cities: Orange, California • Buffalo, New York • Chapel Hill, North Carolina

Conditions: Recurrent Melanoma, Stage IV Melanoma
Interventions: cyclophosphamide, therapeutic autologous lymphocytes, aldesleukin, immunohistochemistry staining method, biopsy, laboratory biomarker analysis, immunologic technique, polymerase chain reaction; Drug · Biological · Other + 2 more
Lead sponsor: Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; Other
Eligibility: 18 Years to 75 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Multiple Myeloma, Refractory Multiple Myeloma, Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
Interventions: plerixafor, filgrastim; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 2
States / cities: Scottsdale, Arizona • Rochester, Minnesota

Conditions: RUNX1 Familial Platelet Disorder
Interventions: G-CSF (filgrastim or biosimilar), Apheresis, Plerixafor; Drug · Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 4 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Disseminated Neuroblastoma, Recurrent Neuroblastoma
Interventions: pyrazoloacridine, filgrastim, autologous bone marrow transplantation, peripheral blood stem cell transplantation, laboratory biomarker analysis, pharmacological study; Drug · Biological · Procedure + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 1 Year to 30 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2002
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Coronary Artery Disease, Coronary Arteriosclerosis, Coronary Atherosclerosis, Coronary Disease
Interventions: MESENDO; Biological
Lead sponsor: TCA Cellular Therapy; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Covington, Louisiana

Conditions: Malignant Pleural Mesothelioma (MPM)
Interventions: cyclophosphamide, CAR T cells; Drug · Biological
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Tooth Loss
Interventions: Sinus lift augmentation and dental implant, Aastrom BRCs; Procedure · Biological
Lead sponsor: University of Michigan; Other
Eligibility: 20 Years to 70 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Lymphoma
Interventions: autologous immunoglobulin idiotype-KLH conjugate vaccine, rituximab, sargramostim; Biological
Lead sponsor: Favrille; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2004
U.S. locations: 60
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Beverly Hills, California + 49 more

Conditions: Covid19
Interventions: Nebulized Platelet Lysate, Nebulized Sterile Saline; Biological · Other
Lead sponsor: Regenexx, LLC; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Broomfield, Colorado

Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: filgrastim, melphalan, bone marrow ablation with stem cell support, peripheral blood stem cell transplantation; Biological · Drug · Procedure
Lead sponsor: Temple University; Other
Eligibility: 16 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1996 – 2006
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma, Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma, Refractory Cutaneous T-Cell Non-Hodgkin Lymphoma
Interventions: Yttrium Y 90 Basiliximab, Carmustine, Etoposide, Cytarabine, Melphalan, Autologous Hematopoietic Stem Cell Transplantation, Laboratory Biomarker Analysis, Pharmacological Study; Biological · Drug · Procedure + 1 more
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Duarte, California

Conditions: Metastatic Melanoma, Stage IV Cutaneous Melanoma AJCC v6 and v7
Interventions: Aldesleukin, Autologous CD8+ Melanoma Specific T Cells, Cyclophosphamide, Ipilimumab, Laboratory Biomarker Analysis; Biological · Drug · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2024
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Severe Combined Immunodeficiency
Interventions: ADA PBSC, ADA Umbilical Cord Blood Cells, Transduced Lymphocytes; Drug
Lead sponsor: National Human Genome Research Institute (NHGRI); NIH
Eligibility: Not listed
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1990 – 2002
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Melanoma
Interventions: dendritic cell-MART-1 peptide vaccine, leukapheresis; Biological · Procedure
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1997
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Breast Cancer
Interventions: Dendritic Cell Vaccination; Biological
Lead sponsor: Quantum Immunologics, Inc.; Other
Eligibility: 18 Years to 85 Years · Female only
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Mobile, Alabama

Conditions: Infantile Malignant Osteopetrosis
Interventions: RP-L401; Biological
Lead sponsor: Rocket Pharmaceuticals Inc.; Industry
Eligibility: 1 Month and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: rituximab, melphalan, Stem Cell, Sargramostim (GM-CSF), 90Y-Zevalin, 111In Zevalin; Biological · Drug · Radiation
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 120 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2018
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Myeloma
Interventions: Lenalidomide, Monocyte derived DCs loaded with KRN7000; Drug · Biological
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Mesolthelioma, Esophageal Cancer, Lung Cancer, Thoracic Sarcomas, Thymoma
Interventions: Celebrex, Tumor cell vaccine; Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 99 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Melanoma, Gastrointestinal Cancer, Breast Cancer, Ovarian Cancer, Pancreatic Cancer
Interventions: Peptide loaded dendritic cell vaccine; Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 70 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Cancer, Relapsed/Refractory Large B-cell Lymphoma (LBCL)
Interventions: Fludarabine (Conditional therapy), Cyclophosphamide Monohydrate (Conditional therapy), firi-cel (Experimental drug); Drug
Lead sponsor: CARGO Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 31
States / cities: Little Rock, Arkansas • Duarte, California • Los Angeles, California + 24 more

Search by objective public record fields.

Dendritic Cell DKK1 Vaccine for Monoclonal Gammopathy and Stable or Smoldering Myeloma

19F Hot Spot MRI of Human Adipose-derived Stem Cells for Breast Reconstruction

RNA-Loaded Dendritic Cell Cancer Vaccine

Therapeutic Autologous Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Stage IV Melanoma

Plerixafor in Treating Patients With Multiple Myeloma Previously Treated With Lenalidomide and Planning to Undergo Autologous Stem Cell Transplant

Protocol Title: Safety and Feasibility of Autologous CD34+ Hematopoietic Stem Cells Mobilization and Apheresis in Participants With RUNX1 Familial Platelet Disorder

Pyrazoloacridine and Stem Cell or Bone Marrow Transplantation in Treating Young Patients With High-Risk Neuroblastoma

Combination Stem Cell (MESENDO) Therapy for Utilization and Rescue of Infarcted Myocardium

Mesothelin-targeted CAR T-cell Therapy in Patients With Mesothelioma

Bone Tissue Engineering Using Autologous Bone Repair Cell (BRC) Therapy for Sinus Floor Bone Augmentation

Vaccine Therapy and Sargramostim Compared With Placebo and Sargramostim Following Rituximab in Treating Patients With Non-Hodgkin's Lymphoma

Nebulized PL for Post-COVID-19 Syndrome

High-Dose Melphalan Followed by Peripheral Stem Cell Transplant in Treating Patients With Amyloidosis

Yttrium Y 90 Basiliximab and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Mature T-cell Non-Hodgkin Lymphoma

CD8+ Antigen-Specific T Cells, Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients With Metastatic Melanoma

Gene Transfer Therapy for Severe Combined Immunodeficieny Disease (SCID) Due to Adenosine Deaminase (ADA) Deficiency: A Natural History Study

Vaccine Therapy in Treating Patients With Stage IV or Relapsed Malignant Melanoma

Cellular Immunotherapy Study With Autologous Dendritic Cells Loaded With Oncofetal Antigen/iLRP in Patients With Metastatic Breast Cancer

A Trial to Evaluate Safety and Efficacy of RP-L401-0120 in Subjects With Infantile Malignant Osteopetrosis

Rituximab, Yttrium Y 90 Ibritumomab Tiuxetan, Melphalan, and Autologous Peripheral Stem Cell Transplant in Treating Patients With Previously Treated Multiple Myeloma

Combination of Lenalidomide and Autologous Mature Dendritic Cells Pulsed With KRN7000 in Myeloma

Tumor Cell Vaccines With ISCOMATRIX Adjuvant and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers and Malignant Pleural Mesotheliomas

Ability of a Dendritic Cell Vaccine to Immunize Melanoma or Epithelial Cancer Patients Against Defined Mutated Neoantigens Expressed by the Autologous Cancer

A Phase 2 Study of Firi-cel in Patients With Relapsed/Refractory Large B-cell Lymphoma